NEW YORK (GenomeWeb News) – The American College of Medical Genetics and Genomics is updating its recommendations on the return of incidental findings results to individuals who have had their genomes or exomes sequenced in the clinical setting.
This article has been updated to include comments from CytoGenX.
CytoGenX, a Stony Brook, NY-based medical genetic testing services company, recently introduced chromosomal microarray analysis for a number of different indications.
Chromosomal microarray analysis should be the first-line genetic test in pregnancies where ultrasound screens uncover signs of fetal abnormalities, according to the American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine.
In an attempt to establish standards and consistency in the growing field of clinical next-generation sequencing, a workgroup for the American College of Medical Genetics and Genomics last week published guidelines in